MARKETS

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

Kgaogelo MatshwiKgaogelo Matshwi
Apr 22, 2024 - 10:05
 0  1
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Read More

Tags:

Previous Article

Blackstone tops Concord's bid for Shakira music owner Hipgnosis

Next Article

REPLY: Value Based Medicine Is Born, the Platform Created by Laife Reply for IEO...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Kgaogelo Matshwi
Kgaogelo Matshwi

Related Posts

Victoria Gold: 2024 First Quarter Results

Victoria Gold: 2024 First Quarter Results

Kgaogelo Matshwi May 14, 2024  0  1

Marquette announces dividend of $0.28 per share

Marquette announces dividend of $0.28 per share

Kgaogelo Matshwi Apr 22, 2024  0  7

Soaring Scam and Fraud Sophistication Remains Top Challenge Threatening to Overwhelm the Global Financial Services Sector

Soaring Scam and Fraud Sophistication Remains Top Chall...

Kgaogelo Matshwi May 7, 2024  0  2